Latest Ceregene Inc. Stories
SAN DIEGO, Feb.
SAN DIEGO, Feb. 3, 2011 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, announced today that it is progressing with enrollment and dosing in its CERE-120 (AAV2-neurturin) Phase 2b multi-center, sham-surgery, double-blinded controlled trial in Parkinson's disease.
SAN DIEGO, Nov. 11, 2010 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, announced today that it has closed its Series D preferred financing in the amount of $11.5 million.
- A person in a secondary role, specifically the second most important character (after the protagonist).